JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.21B |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$2.24B |
| 3 |
Walt Disney
DIS
|
+$2.18B |
| 4 |
Walmart Inc
WMT
|
+$1.96B |
| 5 |
McDonald's
MCD
|
+$1.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$2.77B |
| 2 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$2.64B |
| 3 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$2.5B |
| 4 |
iShares Broad USD High Yield Corporate Bond ETF
USHY
|
+$2.23B |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.61% |
| 2 | Technology | 23.17% |
| 3 | Financials | 10.12% |
| 4 | Consumer Discretionary | 9.84% |
| 5 | Healthcare | 7.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2376
iShares US Healthcare ETF
IYH
$3.9B
| $13.4M | ﹤0.01% |
230,264
+26,286
| +13% | +$1.62M |
2013 Q2
46 quarters
|
|
2377
PUT
lululemon athletica
LULU
$10.2B
| $13.4M | ﹤0.01% |
35,000
-2,900
| -8% | -$947K |
2022 Q3
9 quarters
|
|
2378
CALL
Valero Energy
VLO
$119B
| $13.4M | ﹤0.01% |
109,100
-58,000
| -35% | -$7.76M |
2016 Q3
33 quarters
|
|
2379
PUT
Chevron
CVX
$403B
| $13.4M | ﹤0.01% |
92,300
-32,300
| -26% | -$4.94M |
2013 Q2
46 quarters
|
|
2380
HUB Group
HUBG
$1.76B
| $13.4M | ﹤0.01% |
299,634
+117,047
| +64% | +$5.46M |
2013 Q2
46 quarters
|
|
2381
SSR Mining
SSRM
$6.87B
| $13.4M | ﹤0.01% |
1,918,258
+370,006
| +24% | +$2.3M |
2020 Q3
17 quarters
|
|
2382
Apogee Enterprises
APOG
$752M
| $13.3M | ﹤0.01% |
186,744
+87,356
| +88% | +$6.86M |
2015 Q3
37 quarters
|
|
2383
Vir Biotechnology
VIR
$1.88B
| $13.3M | ﹤0.01% |
1,807,017
+720,690
| +66% | +$5.68M |
2019 Q4
20 quarters
|
|
2384
CALL
Constellation Brands
STZ
$19B
| $13.3M | ﹤0.01% |
60,000
| – | – |
2024 Q3
1 quarter
|
|
2385
Axcelis
ACLS
$4.43B
| $13.2M | ﹤0.01% |
189,568
+10,645
| +6% | +$884K |
2015 Q4
36 quarters
|
|
|
PGRE
2386
DELISTED
Paramount Group
PGRE
| $13.2M | ﹤0.01% |
2,678,713
+160,884
| +6% | +$795K |
2014 Q4
40 quarters
|
|
2387
CALL
Yum China
YUMC
$13.6B
| $13.2M | ﹤0.01% |
273,400
-5,900
| -2% | -$280K |
2023 Q3
5 quarters
|
|
2388
ADMA Biologics
ADMA
$2.22B
| $13.2M | ﹤0.01% |
767,265
+561,310
| +273% | +$10.6M |
2021 Q4
12 quarters
|
|
|
APLS
2389
DELISTED
Apellis Pharmaceuticals
APLS
| $13.1M | ﹤0.01% |
411,549
-3,473,181
| -89% | -$104M |
2017 Q4
28 quarters
|
|
2390
ATI
ATI
$26.5B
| $13.1M | ﹤0.01% |
238,461
-44,799
| -16% | -$2.64M |
2016 Q4
32 quarters
|
|
2391
United Microelectronic
UMC
$58.7B
| $13.1M | ﹤0.01% |
2,021,849
+1,215,849
| +151% | +$8.7M |
2020 Q2
18 quarters
|
|
2392
CVB Financial
CVBF
$3.9B
| $13.1M | ﹤0.01% |
612,503
+249,009
| +69% | +$5.27M |
2013 Q2
46 quarters
|
|
2393
Vanguard FTSE All-World ex-US Small-Cap Index Fund
VSS
$11.7B
| $13.1M | ﹤0.01% |
114,518
+1,712
| +2% | +$206K |
2013 Q3
45 quarters
|
|
2394
Corcept Therapeutics
CORT
$12.8B
| $13.1M | ﹤0.01% |
259,902
+6,832
| +3% | +$358K |
2016 Q4
32 quarters
|
|
2395
First Trust Small Cap Core AlphaDEX Fund
FYX
$1.36B
| $13.1M | ﹤0.01% |
129,585
+42,948
| +50% | +$4.43M |
2022 Q4
8 quarters
|
|
|
RNAM
2396
DELISTED
Avidity Biosciences
RNAM
| $13.1M | ﹤0.01% |
450,144
-16,941
| -4% | -$708K |
2020 Q3
17 quarters
|
|
2397
Acadia Pharmaceuticals
ACAD
$3.43B
| $13.1M | ﹤0.01% |
713,360
+272,236
| +62% | +$4.39M |
2013 Q2
46 quarters
|
|
2398
Blackstone Mortgage Trust
BXMT
$1.83B
| $13.1M | ﹤0.01% |
751,668
+364,699
| +94% | +$6.74M |
2013 Q2
46 quarters
|
|
|
ECHO
2399
EchoStar
ECHO
$28.9B
| $13M | ﹤0.01% |
569,028
+297,424
| +110% | +$7.2M |
2018 Q4
24 quarters
|
|
|
KLC
2400
KinderCare Learning Companies
KLC
$218M
| $13M | ﹤0.01% |
+730,571
| New | +$17.5M |
2024 Q4
0 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2024 Portfolio in Review
As of Q4 2024, JP Morgan Chase held 7,917 positions worth $1.34T, up 2.1% from $1.32T the previous quarter. Its ten largest holdings account for 24% of the portfolio.
JP Morgan Chase's Q4 2024 filing shows 509 new, 3,351 increased, 2,465 reduced and 522 closed positions. Its largest new stake was Primo Brands: 3,989,501 shares worth $123M. The largest sale was Eli Lilly, an estimated $2.77B.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 24% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q4 2024 buy was Primo Brands: 3,989,501 shares worth $123M.
- JP Morgan Chase added most to Broadcom in Q4 2024, an estimated $3.21B increase.
- JP Morgan Chase's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $2.77B.
- JP Morgan Chase fully exited Stericycle Inc in Q4 2024, selling an estimated $183M.
- JP Morgan Chase's ten largest holdings make up 24% of its $1.34T portfolio in Q4 2024.
- JP Morgan Chase opened 509 new positions and closed 522 in Q4 2024.
- JP Morgan Chase's portfolio value rose 2.1% quarter-over-quarter to $1.34T.
Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.